MCID: INF084
MIFTS: 19

Inflammatory Bowel Disease 26

Categories: Gastrointestinal diseases, Genetic diseases, Rare diseases, Bone diseases, Blood diseases, Immune diseases

Aliases & Classifications for Inflammatory Bowel Disease 26

MalaCards integrated aliases for Inflammatory Bowel Disease 26:

Name: Inflammatory Bowel Disease 26 54 12 13 69
Ibd26 12

Classifications:



External Ids:

OMIM 54 612639
Disease Ontology 12 DOID:0110901

Summaries for Inflammatory Bowel Disease 26

Disease Ontology : 12 An inflammatory bowel disease that has material basis in variation in the chromosome region 12q15.

MalaCards based summary : Inflammatory Bowel Disease 26, is also known as ibd26. An important gene associated with Inflammatory Bowel Disease 26 is IBD26 (Inflammatory Bowel Disease-26). The drugs Benzocaine and Adalimumab have been mentioned in the context of this disorder. Affiliated tissues include testes, skin and bone.

Description from OMIM: 612639

Symptoms & Phenotypes for Inflammatory Bowel Disease 26

Clinical features from OMIM:

612639

Drugs & Therapeutics for Inflammatory Bowel Disease 26

Drugs for Inflammatory Bowel Disease 26 (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 84)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Benzocaine Approved Phase 4,Phase 2,Phase 1 1994-09-7, 94-09-7 2337
2
Adalimumab Approved Phase 4,Phase 3,Phase 2 331731-18-1 16219006
3
Azathioprine Approved Phase 4,Phase 3,Phase 2,Phase 1 446-86-6 2265
4
Infliximab Approved Phase 4,Phase 3 170277-31-3
5 Vedolizumab Approved Phase 4,Phase 3 943609-66-3
6
Methotrexate Approved Phase 4 1959-05-2, 59-05-2 126941
7
Cholecalciferol Approved, Nutraceutical Phase 4 67-97-0 6221 10883523 5280795
8
Ergocalciferol Approved, Nutraceutical Phase 4 50-14-6 5280793
9 tannic acid Approved, Nutraceutical Phase 4,Phase 2,Phase 1
10
Vitamin D Approved, Nutraceutical, Vet_approved Phase 4 1406-16-2
11
Folic Acid Approved, Nutraceutical, Vet_approved Phase 4 59-30-3 6037
12
leucovorin Approved, Nutraceutical Phase 4 58-05-9 143 6006
13 Bone Density Conservation Agents Phase 4
14 Ergocalciferols Phase 4
15 Micronutrients Phase 4
16 Trace Elements Phase 4
17 Vitamins Phase 4
18 Gastrointestinal Agents Phase 4,Phase 3
19 Anti-Inflammatory Agents Phase 4,Phase 3,Phase 2
20 Antimetabolites Phase 4,Phase 3,Phase 2,Phase 1
21 Antimetabolites, Antineoplastic Phase 4,Phase 3,Phase 2,Phase 1
22 Antirheumatic Agents Phase 4,Phase 3,Phase 2,Phase 1
23 Dermatologic Agents Phase 4,Phase 3,Phase 2
24 Immunosuppressive Agents Phase 4,Phase 3,Phase 2,Phase 1
25 Adjuvants, Immunologic Phase 4,Phase 3,Phase 2
26 Folic Acid Antagonists Phase 4
27 Nucleic Acid Synthesis Inhibitors Phase 4
28 Vitamin B Complex Phase 4
29 6-Mercaptopurine Phase 4
30 Calciferol Nutraceutical Phase 4
31 Cola Nutraceutical Phase 4,Phase 3
32 Vitamin D2 Nutraceutical Phase 4
33 Folate Nutraceutical Phase 4
34 Vitamin B9 Nutraceutical Phase 4
35
Certolizumab pegol Approved Phase 3,Phase 2 428863-50-7
36
Budesonide Approved Phase 3 51333-22-3 63006 5281004
37
Clarithromycin Approved Phase 3 81103-11-9 84029
38
Clofazimine Approved, Investigational Phase 3 2030-63-9 2794
39
Rifabutin Approved Phase 3 72559-06-9 6323490
40
Aminosalicylic Acid Approved Phase 3 65-49-6 4649
41
Guaifenesin Approved, Vet_approved Phase 3 93-14-1 3516
42 Vaccines Phase 3
43 Anti-Asthmatic Agents Phase 3
44 Autonomic Agents Phase 3
45 Bronchodilator Agents Phase 3
46 glucocorticoids Phase 3,Phase 2
47 Hormone Antagonists Phase 3,Phase 2
48 Hormones Phase 3,Phase 2
49 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2
50 Peripheral Nervous System Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 61)

id Name Status NCT ID Phase Drugs
1 The Effect of Vitamin D3 to Maintain Surgical Remission in Postoperative Crohn's Disease Unknown status NCT02010762 Phase 4 Vitamin D;Placebo
2 A Study to Evaluate Efficacy, of Early Versus Late Use of Vedolizumab in Crohn's Disease: the LOVE-CD Study Recruiting NCT02646683 Phase 4 vedolizumab
3 Triple Combination Therapy in High Risk Crohn's Disease Recruiting NCT02764762 Phase 4 Vedolizumab;Adalimumab;Methotrexate
4 Vedolizumab Intravenous (IV) Dose Optimization in Ulcerative Colitis Recruiting NCT03029143 Phase 4 Vedolizumab IV
5 Comparison of 2 Immunomodulator Withdrawal Schemes for Infliximab Monotherapy in Active Pediatric Crohn's Disease After Thiopurine Failure Terminated NCT01802593 Phase 4 AZATHIOPRINE or METHOTREXATE;AZATHIOPRINE or METHOTREXATE
6 Cimzia Versus Cimzia Plus Azathioprine in the Treatment of Active Crohn's Disease Unknown status NCT01817972 Phase 3 Azathioprine
7 Efficacy and Safety of Two Regimens of Maintenance Therapy in Children With Crohn Disease Unknown status NCT01559142 Phase 3 Infliximab with azathioprine (IIFX + AZA);Infliximab (IFX alone)
8 Protecting Young Special Risk Females From Cervical Cancer Through Human Papilloma Virus (HPV) Vaccination Completed NCT00964210 Phase 3 Licensed quadrivalent HPV vaccine, Gardasil
9 Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo), Following 3 Doses of Active Drug (CDP870). Completed NCT00152425 Phase 3 Certolizumab Pegol (CDP870)
10 A Study to Test the Effect of CDP870 in the Treatment of Crohn's Disease Over 26 Weeks, Comparing CDP870 to a Dummy Drug (Placebo) Completed NCT00152490 Phase 3 Certolizumab Pegol (CDP870)
11 A follow-on Safety Study of CDP870 in Subjects With Crohn's Disease (CD) Who Have Completed a 26-week Double Blind Study CDP870-031 [NCT00152490] or CDP870-032 [NCT00152425] Completed NCT00160524 Phase 3
12 SOIBD Collagenous Colitis Maintenance Study Completed NCT01278082 Phase 3 Budesonide;Placebo
13 Efficacy and Safety of Adalimumab in Pediatric Subjects With Moderate to Severe Crohn's Disease Completed NCT00409682 Phase 3
14 Certolizumab in Crohn's Disease Patients With Loss of Response or Intolerance to Infliximab Completed NCT00308581 Phase 3
15 A Study to Evaluate the Effectiveness and Safety of Infliximab in Chinese Patients With Active Ulcerative Colitis Completed NCT01551290 Phase 3 Infliximab;Placebo
16 A Study to Evaluate Safety of Long Term Therapy of Certolizumab Pegol Patients With Crohn's Disease Completed NCT00552344 Phase 3
17 Clinical Study of TA-650 in Pediatric Patients With Crohn's Disease Completed NCT01580670 Phase 3 TA-650
18 OD vs. TID Dosing With Mesalazine Granules in Active Ulcerative Colitis Completed NCT00449722 Phase 3 mesalazine
19 Trial Comparing Infliximab and Infliximab and Azathioprine in the Treatment of Patients With Crohn's Disease na�ve to Both Immunomodulators and Biologic Therapy (Study of Biologic and Immunomodulator Naive Patients in Chrohn's Disease: SONIC Completed NCT00094458 Phase 3 infliximab (IFX) placebo infusion; azathioprine (AZA) caps
20 Clinical Study of TA-650 in Pediatric Patients With Ulcerative Colitis Completed NCT01585155 Phase 3 TA-650
21 Efficacy and Safety of Anti-MAP Therapy in Adult Crohn's Disease Recruiting NCT01951326 Phase 3 RHB-104;Placebo
22 Open Label Efficacy and Safety of Anti-MAP (Mycobacterium Avium Ssp. Paratuberculosis) Therapy in Adult Crohn's Disease Recruiting NCT03009396 Phase 3 RHB-104
23 A Study Comparing the Efficacy and Safety of Etrolizumab With Adalimumab and Placebo in Participants With Moderate to Severe Ulcerative Colitis (UC) in Participants Naive to Tumor Necrosis Factor (TNF) Inhibitors (Study #1) Recruiting NCT02163759 Phase 3 Adalimumab;Etrolizumab
24 Effect of Intravenous (IV) Vedolizumab on Mucosal Healing in Crohn's Disease Active, not recruiting NCT02425111 Phase 3 Vedolizumab
25 Study to Evaluate the Safety and Efficacy of Adalimumab in Chinese Subjects With Moderate to Severe Crohn's Disease Active, not recruiting NCT02499783 Phase 3
26 Vedolizumab Intravenous (IV) Compared to Placebo in Chinese Participants With Crohn's Disease Not yet recruiting NCT03234907 Phase 3 Vedolizumab IV;Placebo
27 A Study With Pentasa in Patients With Active Crohn's Disease Terminated NCT00862121 Phase 3 Pentasa;Placebo
28 Efficacy, Safety and Tolerability of Propionyl-L-Carnitine Hydrochloride in Patients With Mild Ulcerative Colitis Terminated NCT01538251 Phase 3 Propionyl-L-Carnitine;Placebo
29 Assessing the Safety/Efficacy of Asacol® Given Every 12 Hours to Children and Adolescents for the Maintenance of Remission of Ulcerative Colitis Terminated NCT01004185 Phase 3 Asacol 400 mg;Asacol 400 mg
30 A Study to Investigate the Safety and Efficacy of LT-02 in Patients With Mesalamine Refractory Ulcerative Colitis (UC) Terminated NCT02849951 Phase 3 LT-02;LT-02 Placebo
31 Calprotectin-Directed Humira® Maintenance Therapy (CADHUM) Withdrawn NCT01674413 Phase 3 Adalimumab;Adalimumab PRN;Placebo
32 Maintenance Study of Certolizumab Pegol (CZP) in Crohn's Disease Completed NCT00329550 Phase 2
33 Maintenance Study Including Re-induction Therapy for Patients Who Did Not Show a Clinical Effect in Study C87037 (NCT00291668) Completed NCT00329420 Phase 2
34 Evaluation of Efficacy and Safety of MEDI2070 in Patients With Active, Moderate-to-severe Crohn's Disease. Completed NCT01714726 Phase 2 MEDI2070;placebo;MEDI2070
35 The Safety And Efficacy Of Maintenance Therapy With CP-690,550 Completed NCT01393899 Phase 2 Placebo;CP-690,550;CP-690,550
36 A Study of Safety and Effectiveness of Ustekinumab in Patients With Moderate to Severe Active Crohn's Disease Who Have Been Previously Treated With Anti-TNF Therapy Completed NCT00771667 Phase 2 Placebo (IP);Ustekinumab 1mg/kg (IP);Ustekinumab 3 mg/kg (IP);Ustekinumab 6 mg/kg (IP);Placebo IV - Responder - Placebo SC (MP);Placebo IV - Nonresponder - Ustekinumab 270/90 mg SC (MP);Ustekinumab IV - Responder - Placebo SC (MP);Ustekinumab IV - Responder - Ustekinumab 90mg SC (MP);Ustekinumab IV - Nonresponder - Placebo SC (MP);Ustekinumab IV - Nonresponder - Ustekinumab 90mg SC (MP)
37 Study to Evaluate the Pharmacokinetics, Safety and Efficacy of Two Treatment Modules in Chinese Subjects With Moderate to Severe Crohn's Disease Completed NCT02015793 Phase 2
38 Efficacy and Safety of Etrasimod (APD334) in Inflammatory Bowel Disease Patients With Active Skin Extra-intestinal Manifestations Recruiting NCT03139032 Phase 2 APD334
39 The Efficacy of Cobitolimod in Patients With Moderate to Severe Active Ulcerative Colitis Recruiting NCT03178669 Phase 2 cobitolimod;Placebo
40 Open-label Extension Study to Assess Safety and Tolerability of LYC-30937-EC in Subjects With Active Ulcerative Colitis Recruiting NCT02764229 Phase 2 LYC-30937-EC
41 Study to Evaluate the Testicular Safety of Filgotinib in Adult Males With Moderately to Severely Active Ulcerative Colitis Recruiting NCT03201445 Phase 2 Filgotinib;Placebo;Standard of Care
42 Efficacy and Safety of AbGn-168H in Patients With Moderate to Severe Active, Anti-TNF Alpha and/or Anti-integrin Refractory Ulcerative Colitis Not yet recruiting NCT03298022 Phase 2
43 Dose Finding Study of BIRB 796 BS in Patients With Moderate to Severe Crohn's Disease Terminated NCT02209792 Phase 2 Placebo;BIBR 796 BS, 5 mg;BIBR 796 BS, 20 mg
44 Azathioprine in the Prevention of Ileal Crohn's Disease Postoperative Recurrence. Terminated NCT02247258 Phase 2 Azathioprine;Azathioprine in case of endoscopic recurrence
45 Safety and Efficacy of Treatment With Interferon Beta-1a Rebif® in Patients With Crohn's Disease Terminated NCT00304252 Phase 2 Interferon beta-1a
46 Growth Hormone and Exclusion Diet Therapy in Juvenile Crohn's Disease Withdrawn NCT01647412 Phase 2 Growth Hormone
47 Azathioprine & Allopurinol in Inflammatory Bowel Disease Patients Completed NCT00849368 Phase 1 Azathioprine / Allopurinol
48 Extracorporeal Photopheresis to Maintain Symptoms Remission During Steroid Withdrawal in Patients With Steroid-Dependent Crohn's Disease Completed NCT00056355 Phase 1 UVADEX and UVAR XTS Photopheresis System
49 Switching From Adalimumab to Infliximab Unknown status NCT01338740 Adalimumab and Infliximab
50 Efficacy Study of T2 Versus AZA to Maintain Clinical and Endoscopic Remission in Postoperative Crohn's Disease Unknown status NCT01015391 T2;Azathioprine

Search NIH Clinical Center for Inflammatory Bowel Disease 26

Genetic Tests for Inflammatory Bowel Disease 26

Anatomical Context for Inflammatory Bowel Disease 26

MalaCards organs/tissues related to Inflammatory Bowel Disease 26:

39
Testes, Skin, Bone

Publications for Inflammatory Bowel Disease 26

Variations for Inflammatory Bowel Disease 26

Expression for Inflammatory Bowel Disease 26

Search GEO for disease gene expression data for Inflammatory Bowel Disease 26.

Pathways for Inflammatory Bowel Disease 26

GO Terms for Inflammatory Bowel Disease 26

Sources for Inflammatory Bowel Disease 26

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....